[{"NetIncomeLossConverted_1_Q2_USD":-60974000.0,"NetIncomeLossConverted_2_Q2_USD":-115454000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":-67530000.0,"CommonStockSharesOutstanding_0_Q2_shares":139233450.0,"StockholdersEquity_0_Q2_USD":1163419000.0,"EarningsPerShareBasic_1_Q2_USD":-0.53,"EarningsPerShareBasic_2_Q2_USD":-1.03,"Assets_0_Q2_USD":1258544000.0,"CommonStockSharesConverted_0_Q2_shares":139233450.0,"Ticker":"ALLO","CIK":"1737287","name":"ALLOGENE THERAPEUTICS, INC.","OfficialName":"Allogene Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1134878416.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20200805"}]